Featured
TP53 Pathway LinkedIn HQ.jpg
Oncology
TP53, the most altered gene in oncology
Oncology
Oncology
Lifyorli-Figure (3).jpg
Oncology
Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality
Oncology
Oncology
oveporexton Figure.jpg
Chronic Diseases
Oveporexton Could be a Game-changer for Narcolepsy Type 1
Chronic Diseases
Chronic Diseases
The Problem with Primary Market Research
R&D Insights
The Problem with Primary Market Research
R&D Insights
R&D Insights
Casgevy-Figure.jpg
Chronic Diseases
Gene Therapies for Sickle Cell Disease: Expensive but Worth It
Chronic Diseases
Chronic Diseases
Keytruda-paclitaxel-bevacizumab-Figure.jpg
Oncology
Keytruda Grabs its 42nd Approval in PD-L1+ PROC
Oncology
Oncology
Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D
R&D Insights
Plan for the Best, Prepare for the Worst - Handling Uncertainty in R&D
R&D Insights
R&D Insights
Finding the Best R&D Opportunities
R&D Insights
Finding the Best R&D Opportunities
R&D Insights
R&D Insights
Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH
Chronic Diseases
Using Equinox Drivers Charts to Understand Fabhalta's Success in PNH
Chronic Diseases
Chronic Diseases
Measuring Risk in R&D
R&D Insights
Measuring Risk in R&D
R&D Insights
R&D Insights
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC
Oncology, R&D Insights
Oncology, R&D Insights
Screenshot 2025-10-30 154345.png
Oncology, R&D Insights
What indications should we focus on?
Oncology, R&D Insights
Oncology, R&D Insights
 

Check out our case studies and articles in oncology and chronic disease over the years

Oncology

Chronic Disease

R&D Insights